Comparison · NCT00433199-sae
T-Gel 1.62% vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. T-Gel 1.62% vs Placebo: serious adverse events. Trial comparisons, record NCT00433199-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00433199-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0214 | 0.00916 | 0.049 | wilson | |
| Risk in group 2 | 0.025 | 0.00443 | 0.129 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00363 | -0.108 | 0.0308 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.855 | 0.103 | 7.13 | log | |
| Odds ratio, group 1 over group 2 | 0.852 | 0.0969 | 7.49 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on T-Gel 1.62% than on Placebo | 275 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | T-Gel 1.62% | Testosterone (T): daily dose of 2.50 g testosterone gel 1.62% administered during the Double-Blind period and the Open-Label period. | 5 | 234 | EG001 |
| Group 2 | Placebo | Placebo comparator administered during the Double-Blind period only | 1 | 40 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- The adverse events presented were collected from start of drug treatment to the end of the double-blind treatment period (from Day 0 to Day 182).
Source ClinicalTrials.gov
Trial
- Title
- Testosterone Treatment for Hypogonadal Men
- NCT number
- NCT00433199
- Phases
- PHASE3
- Conditions
- Hypogonadism
- Interventions
- Testosterone (T) Gel 1.62%, Placebo
- Lead sponsor
- Abbott
- Results first posted
- 2011-12-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00433199?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00433199-sae